Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
James Udelson MD
James E. Udelson MD Advisory Board
Benjamin Scirica MD
Benjamin Morgan Scirica MD Associate Editor
Ileana Piña MD, MPH, FAHA, FACC
Ileana L. Piña MD, MPH, FAHA, FACC Advisory Board
See All Experts
featured
Published in Cardiology

Expert Opinion / Interview · January 27, 2014

Heart Failure With Preserved Ejection Fraction: Part 1

Barry Borlaug MD
Joerg Herrmann MD

 

 Save  Recommend
 Share

Additional Info

  1. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community. Circulation.1998;98:2282-2289.

  2. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-259.

  3. Borlaug BA, Lam CS, Roger VL, et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;28;54(5):410-418.

  4. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56(11):845-854.

  5. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation. 2006;114(20):2138-2147.

  6. Abudiab MM, Redfield MM, Melenovsky V, et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15(7):776-785.

  7. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268-1277.

  8. Borlaug BA, Melenovsky V, Marhin T, et al. Sildenafil inhibits β-adrenergic–stimulated cardiac contractility in humans. Circulation. 2005;112(17):2642-2649.

  9. Ennezat PV, Lefetz Y, Marechaux S, et al. Left ventricular abnormal response during dynamic exercise in patients with heart failure and preserved left ventricular ejection fraction at rest. J Card Fail. 2008;14(6):475-480.

  10. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107(5):714-720.

  11. Haykowsky MJ, Brubaker PH, John JM, et al. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. 2011;58(3):265-274.

  12. Scantlebury DC, Borlaug BA. Why are women more likely than men to develop heart failure with preserved ejection fraction? Curr Opin Cardiol. 2011;26(6):562-568.

  13. Borlaug BA, Redfield MM, Melenovsky V, et al. Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail. 2013;6(5):944-952.

  14. Fujimoto N, Borlaug BA, Lewis GD, et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation. 2013;127(1):55-62.

  15. Shah AM, Shah SJ, Anand IS, et al. Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circ Heart Fail. 2014;7(1):104-115.

  16. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271.

Disclosure statements are available on the authors' profiles:

Joerg Herrmann MD

Further Reading

Most Read This Week

Recently Updated